TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ASTRAZENECA TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ASTRAZENECA Stock
Certificat
DE000SD9JQM7
| Market Closed - Deutsche Boerse AG 15:41:20 2024-05-30 EDT | ||
| 5.72 EUR | +1.78% |
|
| Current month | -1.72% | ||
| 1 month | -1.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-05-30 | 5.72 | +1.78% |
| 24-05-29 | 5.62 | -1.58% |
| 24-05-28 | 5.71 | -6.39% |
| 24-05-27 | 6.1 | +0.66% |
| 24-05-24 | 6.06 | -0.33% |
Delayed Quote Deutsche Boerse AG
Last update May 30, 2024 at 03:41 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SD9JQM |
| ISIN | DE000SD9JQM7 |
| Date issued | 2020-12-22 |
| Strike | 7,181 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.43 € |
|---|---|
| Lowest since issue | 0.64 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
151.7
USD
Average target price
172
USD
Spread / Average Target
+13.40%
- Stock Market
- Certificates
- Certificat
